The HHS Peptide Policy Landed October 28. Our Accredited Course Was Updated Immediately.
On October 28, 2026, the Secretary of Health and Human Services signed an interim enforcement discretion policy covering six peptides: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. It published October 30 in the Federal Register under docket HHS-OASH-2026-0496.
Our course was updated the same day. If you are enrolled, the new material is already in your account, in the main peptide module and in Breaking News.
That is the whole argument for how we build this course, so here is how we make the most complete and transparent accredited training course on this subject matter.
What the update actually gave learners
Most of the coverage got the headline and missed the parts that change what a clinic may lawfully do tomorrow. Here is what is in the policy appendix, and what our learners now have in front of them.
- Routes are limited per substance, and they are not the same. BPC-157 covers subcutaneous, intramuscular, oral and topical. TB-500 and MOTS-c are subcutaneous or intramuscular only. Epitalon is subcutaneous or intramuscular, dispensed in intermittent courses. Semax is intranasal only. KPV is topical and oral only.
- Injectable Semax and injectable KPV are not covered at all. A clinic injecting either one is in exactly the position it was in on October 27, except that it now believes otherwise.
- There is no intravenous route for any of the six. Not one. If an IV clinic is offered any of these for a bag, it is outside the policy entirely.
- Single active ingredient only. No blends, no stacks, no combination vials. A large share of what is actually sold in this market is stacked, and none of it is covered.
- Patient-specific prescription required. There is no office stock.
And the point our learners heard first
This is not an approval. Nothing was added to any bulks list, the statute did not move, and compounding these in the United States is still not legal. One department announced it does not intend to prosecute. That is a different thing, it can be withdrawn without notice, and it binds no state board.
Alabama, Mississippi and South Carolina have each already told their licensees that under no circumstances may they compound, administer, dispense or recommend a non-FDA-approved peptide.
Why peptide prescriber training has to be maintained, and accredited, not learned from a supplier channel…
Most continuing education in this space is a snapshot. It was accurate the quarter it was written. Consider what has happened since the summer.
- An FDA advisory committee voted on seven peptides in July
- Three state boards issued categorical prohibitions in the space of three months
- A federal appeals court closed the last challenge to the GLP-1 shortage delistings in August
- Five compounding pharmacies recalled contaminated injectable product between August and October
- FDA added a boxed warning to an intravenous iron product in September
- And then this
A course written in June would be wrong in four places by now, and the people relying on it would not know which four.
Our course is reviewed and revised in the first week of every month, with a Breaking News module that carries developments as they happen. Enrolled learners keep access as it changes. That is not a feature we added for marketing. It is the only way to teach a subject where a single letter can change what is lawful overnight.
Peptide certification versus accredited training
A word on the term, because it is what most people search.
There is no recognized certification in peptide therapy. No board certifies it, and any program selling you one is selling a certificate with no issuing authority behind it. What exists is accredited training, and that is what this is.
Beyond Injectables: Peptides, IVs, GLP-1s and the Wellness Frontier
11.5 AMA PRA Category 1 Credits and 11.5 ANCC contact hours, including 6.5 pharmacotherapeutic contact hours, jointly accredited by Amedco LLC. You finish with documented accredited credit and a defensible framework, not a logo.
Who this is for
Physicians, nurse practitioners, physician assistants and registered nurses working in medical spas, IV therapy clinics, longevity and wellness practices, aesthetic medicine, and concierge or direct-pay settings. It is equally useful to the clinician deciding whether to enter this market and to the one already running a service menu who needs to know which parts of it will survive.
The course covers each peptide individually with a verdict and the reasoning behind it, the three-part eligibility test that decides whether any compound may be lawfully compounded, sourcing and compounder vetting, medical director exposure, and the state-by-state picture as it actually stands.
This material is continuing medical education and general information. It is not legal advice, it creates no professional relationship, and it guarantees no regulatory or legal outcome. Verify current federal and state requirements with your own counsel. Primary sources for this post: the HHS enforcement discretion policy and its appendices, and the Federal Register notice of availability, FR Doc 2026-22192.